acebutolol vs azilsartan
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acebutolol and azilsartan. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Sectral
Edarbi
Acebutolol is a medicine that helps lower blood pressure and control irregular heartbeats. It belongs to a class of drugs called beta-blockers.
No summary available.
Acebutolol is used to treat high blood pressure in adults. It can be used alone or with other blood pressure medicines. Acebutolol is also used to manage irregular heartbeats called ventricular arrhythmias. It helps to reduce the number of these irregular beats.
Information not available.
Acebutolol works by blocking the effects of certain natural chemicals in your body, like adrenaline, on the heart and blood vessels. This helps to slow down the heart rate and lower blood pressure. It also helps to make the heart beat more regularly.
Information not available.
No common side effects listed.
- • Dizziness
- • Fatigue
- Cognitive Disorder 620
- Fall 615
- Orthostatic Hypotension 573
- Balance Disorder 568
- Constipation 565
No adverse event reports.
You should not take acebutolol if you have a very slow heart rate, second- or third-degree heart block, heart failure, or cardiogenic shock.
No specific warnings noted.
Tell your doctor if you are pregnant or plan to become pregnant. It is not known if acebutolol will harm an unborn baby. Talk to your doctor about the risks and benefits of taking acebutolol while breastfeeding.
No pregnancy information available.
Also Compare, Nearby Drugs
Compare azilsartan with
How to Read This acebutolol vs azilsartan Comparison
acebutolol is classified in the Beta-1 Selective Blocker with ISA drug class, while azilsartan sits within the Angiotensin II Receptor Blocker (ARB) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acebutolol has 2,941 submissions while azilsartan has 0. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acebutolol or azilsartan.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.